
TECHNOLOGY READINESS LEVELS (TRLs)

Technology readiness levels (TRLs) is a measure of estimating technology maturity of core technologies in a program during the selection process and in subsequent monitoring and evaluation phases until these technologies, or products utilizing them, attain market readiness. Originally introduced by NASA, the TRL scale is a metric with nine technology readiness levels for describing the maturity of a technology from ideation stage (TRL-1) to highest degree of application/commercial readiness (TRL-9). Levels in between covers establishment of proof of concepts, prototype developments, functional validations from models to real operational environments and clearances of mandatory regulatory barriers between levels towards market introduction of these technologies/products.



NASA Technology Readiness Levels

References:

- a.) Gustav Notander, EIT Health, European Union (Technology Readiness Levels TRL-NASA's contribution to Horizon 2020.
- b.) Technology Readiness Assessment (TRA) Guidance. U.S. Department of Defense, (2011).

- c.) Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India (2016), Department of Biotechnology, India.
- d.) The TRL Scale as a Research & Innovation Policy Tool-EARTO Recommendations (2014).
- e.) TRL-NASA ESTO (https://www.nasa.gov/pdf/458490main_TRL_Definitions.pdf).
- f.) Banke, J., August 20, 2010, Technology Readiness Levels Demystified, NASA.
- g.) Crop Research Technology Readiness Level (TRL)(2016)-United State Department of Agriculture National Institute of Food and Agriculture Institute of Food Production and Sustainability.

Technology Readiness Levels Required for Applications

Sl. No	Thematic Area	Stage	Required TRL	Definition
1	Drugs (including Drug Delivery)	Proof of Concept Established	TRL-4	Efficacy,& safety of candidate drug formulation is demonstrated in a defined animal model (Results of formulation studies, pharmacokinetic studies & ADME, PD, safety of candidate formulations at preliminary level and efficacy in <i>in-vivo</i> disease model)
2	Regenerative Medicine	Proof of Concept Established	TRL-4	Candidate Optimization and Non-GLP in vivo Demonstration of Activity and Efficacy Animal Models: Initiate development of appropriate and relevant animal models(s) for the desired indications and perform non-GLP in vivo toxicity and efficacy. Assays: Initiate development of appropriate and relevant assays and associated reagents for the desired indications. Manufacturing: Manufacturing: Manufacturing: of bulk product and proposed formulated product. Demonstrate non-GLP in

				vivo activity and potential for efficacy consistent with the product's intended use (i.e., dose, schedule, duration, route of administration and route). Conduct initial non-GLP toxicity studies and determine pharmacodynamics and pharmacokinetics and/or immune response in appropriate animal models (as applicable). Initiate experiments to determine assays, parameters, surrogate markers, correlates of protection and endpoints to be used during non-clinical
				and clinical studies to further evaluate and characterize candidate(s).
3	Vaccines	Proof of Concept Established	TRL-4	Efficacy & safety of vaccine candidate is demonstrated in a defined animal model (Results of serological studies in different animals at preliminary level and efficacy in defined <i>in vivo</i> model, Manufacturing and QC release of vaccine for Studies, Scale up Development).
4	Clinical Trials	Early Stage Validation	TRL-5	Pre-clinical studies including GLP efficacy, acute and chronic toxicity, all the studies mandatory for safe exposure to humans such as repeat dose toxicity (RDT) and safety in animal model producing sufficient data for DCGI application for clinical trials.
5	Devices & Diagnostics	Proof of Concept Established	TRL-4	MedicalDevices/DiagnosticDevices:FunctionalPrototypedevelopedbyintegrationofdifferent

				modules and safety, efficacy and performance of candidate
				device or system demonstrated in a defined laboratory, Simulated
				Environment or animal model (with Institutional Animal
				Ethics Committee approvals). Diagnostic Kits: Optimized
				core components integrated
				into the kit or platform (Microfluidics/ filter paper/
				LFA etc) along with the reagents to
				come up with a functional prototype of the kit.
				Integrated system tested in house with metabolite,
				serial dilution or ELISA or
				spiked biological samples. Biomedical Implants:
				Material safety and or imaging compatibility proven
				in <i>in vivo</i> small animal model study (with Institutional
				Animal Ethics Committee
				approvals). Functional Prototype implant device
				developed as per the design in a near GMP condition.
				Sterilization and packaging established.
6	Bioinformatics	Early Stage Validation	TRL-5	Developed software technologies to integrate with
				different aspects of existing system; Developed software
				technologies implementations
				conform to target environment interfaces;
				experiments with realistic problems; rigorous alpha
7	Industrial	Droof of	TDI 4	testing.
7	Industrial Biotechnology/Secondary	Proof of Concept	TRL-4	Concept proven from lab scale to Bioreactor level
	Agriculture	Established		experiments under optimized conditions at less than 100L.

				NT
				Necessary approvals to be
				obtained for using GMOs
0	A . 1,	T (C)	TDI 5	(RCGM/GEAC).
8	Agriculture	Late Stage	TRL 5	Marker Assisted Selection:
		Research		Development of homozygous
				lines for gene of interest
				through marker assisted
				foreground and background
				selection.
				Transgenics/ Gene Edits:
				Integration and the expression
				analysis of the trans/cis- gene
				in the T1 generation.
				Bio control: In vitro
				evaluation and screening of
				local strains against target
				pathogens or insects.
				<u>Tissue Culture:</u> Optimization of conditions for hardening
				and establishment of plants
				inside greenhouse/ net house.
9	Aqua Culture and	Early Stage	TRL 5	Component and or basic
9	Fisheries	Validation		subsystem technology tested
	Tisheres	Validation		/validated in controlled
				conditions in smaller tanks in
				laboratory/hatchery with
				proper control following
				statistically designed
				protocols.
10	Veterinary	Early Stage	TRL 5	Drugs/vaccines:
	•	Validation		Demonstration of proof of
				concept (PoC) in limited
				number of animals (by
				serological studies). Working
				on feasible formulation
				development and conducting
				safety and efficacy studies).
				<u>Devices</u>
				"High-fidelity" laboratory
				integration of components.
				The basic technological
				components are integrated
				with reasonably realistic
				supporting elements so they
				can be tested in a simulated
				environment.

				Diagnostics Establish all the diagnostic kits to have desired specificity & sensitivity based on the data generated.
11	Clean Energy &	Proof of	TRL-4	Demonstrated technology at
	Environmental Solutions	Concept		pilot stage.
		Established		